Everolimus versus sirolimus for angiomyolipoma associated with tuberous sclerosis complex: a multi-institutional retrospective study in China

Table 2 Treatment efficacy

	Sirolimus	Everolimus	P-Value
3 months
Decrease from baseline (mean ± SD, %)	35.4 ± 16.2	42.0 ± 17.6	0.06
No. PR /Total No. patients (%)	11/33 (33)	42/91 (46)	0.20
6 months
Decrease from baseline (mean ± SD, %)	38.1 ± 17.2	48.5 ± 20.6	0.01
No. PR /Total No. patients (%)	12/32 (38)	46/84 (55)	0.10
12 months
Decrease from baseline (mean ± SD, %)	45.1 ± 13.9	56.7 ± 21.2	0.02
No. PR /Total No. patients (%)	12/23 (52)	34/49 (69)	0.16
24 months
Decrease from baseline (mean ± SD, %)	52.5 ± 14.1	62.5 ± 15.3	0.09
No. PR /Total No. patients (%)	6/10 (60)	17/21 (81)	0.38

Target angiomyolipomas in the kidney in each patient were visualized by CT or MRI at baseline and at 3, 6, 12, 18 and 24 months and the longest diameter of each angiomyolipoma was measured
PR partial response, defined as a reduction in angiomyolipoma volume (sum of volumes of all target angiomyolipomas identified at baseline) of 50% or more relative to baseline and absence of angiomyolipoma progression

ISSN: 1750-1172